#United States #Clinical Trials #Doylestown #Pinnacle Medicines #Oral Peptide

Pinnacle Medicines Raises $89 Million to Advance Innovative Oral Peptide Therapeutics

Pinnacle Medicines, a forefront biotechnology company, has recently announced the successful closure of an oversubscribed Series B financing round, amassing a substantial $89 million. This critical funding will significantly bolster the company's ongoing efforts to develop and progress its oral peptide therapeutic pipeline into clinical trials. The financing round was co-led by notable investors LAV and Foresite Capital, with the contribution of additional firms including Quan Capital, Hankang Capital, RA Capital Management, and Logos Capital, alongside existing investors like OrbiMed.

The raised funds are poised to support Pinnacle's ambition to push its leading programs through clinical proof of concept. The initial concentration will be on addressing diseases within the immunology and cardiometabolic realms, which are increasingly pressing areas in healthcare. By enhancing its proprietary peptide discovery platform and its R&D capabilities, Pinnacle Medicines aims to introduce a new category of oral peptide treatments that enhance patient accessibility and ease of use.

Jonathan Wang, Pinnacle's Chief Executive Officer, expressed enthusiasm about the funding achievement, stating, "This financing marks an important milestone for Pinnacle Medicines and reflects strong conviction in the transformative potential of oral peptide therapeutics. We are focused on translating our vision into clinical proof of concept and delivering transformative medicines for patients."

Furthermore, Dr. Chengzao Sun, the Chief Scientific Officer and co-founder, elaborated on the company’s unique technological approach. He noted the integration of advanced AI technologies combined with physics-based simulations in the drug development process, which enables the rational design and optimization of peptide therapeutics. The team has been bolstered by experienced professionals across critical disciplines, reinforcing their aspirations to bring forth an innovative generation of oral medications targeting chronic diseases.

Investors have shown remarkable confidence in Pinnacle Medicines. Cindy Xiong, a partner at Foresite Capital, voiced her excitement about the company's potential, remarking, "We are very excited about the future of oral peptide therapeutics, and Pinnacle Medicines is emerging as a leader in this field. The team brings deep experience in peptide drug development and has demonstrated a remarkable ability to rapidly build both a differentiated discovery platform and a promising first-in-class pipeline."

David Wang, M.D., Ph.D., a senior managing director at OrbiMed, also shared in the sentiment, emphasizing their continued support since Pinnacle's inception. "Oral peptide therapeutics have the potential to reshape treatment paradigms across multiple disease areas, and we are excited to continue supporting the company as it advances its pipeline toward clinical proof of concept."

Pinnacle Medicines is on track to revolutionize how peptide medicines are delivered. By focusing on achieving biologic-level effectiveness and safety through convenient oral dosing, they are well-positioned to meet urgent health needs effectively. The company's future endeavors will be closely monitored by industry stakeholders, as their innovative approach could pave the way for groundbreaking therapies that will significantly benefit patients suffering from chronic conditions.

For additional information about Pinnacle Medicines and their ongoing projects, please visit their official website.